Nephrotic Syndrome – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Nephrotic Syndrome – Pipeline Review, H1 2020’, provides an overview of the Nephrotic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome

– The report reviews pipeline therapeutics for Nephrotic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Nephrotic Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Nephrotic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Nephrotic Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nephrotic Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nephrotic Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adare Pharmaceuticals Inc

Asahi Kasei Pharma Corp

Bristol-Myers Squibb Co

ChemoCentryx Inc

Pharmapraxis

SynAct Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nephrotic Syndrome - Overview

Nephrotic Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nephrotic Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nephrotic Syndrome - Companies Involved in Therapeutics Development

Adare Pharmaceuticals Inc

Asahi Kasei Pharma Corp

Bristol-Myers Squibb Co

ChemoCentryx Inc

Pharmapraxis

SynAct Pharma AB

Nephrotic Syndrome - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mizoribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nephrotic Syndrome - Dormant Projects

Nephrotic Syndrome - Product Development Milestones

Featured News & Press Releases

Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Nephrotic Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Nephrotic Syndrome – Pipeline by Adare Pharmaceuticals Inc, H1 2020

Nephrotic Syndrome – Pipeline by Asahi Kasei Pharma Corp, H1 2020

Nephrotic Syndrome – Pipeline by Bristol-Myers Squibb Co, H1 2020

Nephrotic Syndrome – Pipeline by ChemoCentryx Inc, H1 2020

Nephrotic Syndrome – Pipeline by Pharmapraxis, H1 2020

Nephrotic Syndrome – Pipeline by SynAct Pharma AB, H1 2020

Nephrotic Syndrome – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Nephrotic Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports